429 related articles for article (PubMed ID: 25394774)
21. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Lin CJ; Lee CC; Shih YL; Lin TY; Wang SH; Lin YF; Shih CM
Free Radic Biol Med; 2012 Jan; 52(2):377-91. PubMed ID: 22094224
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
[TBL] [Abstract][Full Text] [Related]
24. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Kaneko M; Kaneko S; Suzuki K
Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
[TBL] [Abstract][Full Text] [Related]
25. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death.
Li Z; Jaboin J; Dennis PA; Thiele CJ
Cancer Res; 2005 Mar; 65(6):2070-5. PubMed ID: 15781614
[TBL] [Abstract][Full Text] [Related]
26. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity.
Scala S; Wosikowski K; Giannakakou P; Valle P; Biedler JL; Spengler BA; Lucarelli E; Bates SE; Thiele CJ
Cancer Res; 1996 Aug; 56(16):3737-42. PubMed ID: 8706017
[TBL] [Abstract][Full Text] [Related]
27. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Li Z; Oh DY; Nakamura K; Thiele CJ
Cancer; 2011 Dec; 117(23):5412-22. PubMed ID: 21590687
[TBL] [Abstract][Full Text] [Related]
28. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
[TBL] [Abstract][Full Text] [Related]
29. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
30. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
31. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
33. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel candidate compounds targeting TrkB to induce apoptosis in neuroblastoma.
Nakamura Y; Suganami A; Fukuda M; Hasan MK; Yokochi T; Takatori A; Satoh S; Hoshino T; Tamura Y; Nakagawara A
Cancer Med; 2014 Feb; 3(1):25-35. PubMed ID: 24403123
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
36. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
38. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
39. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
40. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells.
Matsumoto K; Wada RK; Yamashiro JM; Kaplan DR; Thiele CJ
Cancer Res; 1995 Apr; 55(8):1798-806. PubMed ID: 7712490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
